Ajay J Iyengar1, David S Winlaw2, John C Galati3, Gavin R Wheaton4, Thomas L Gentles5, Leeanne E Grigg6, Robert N Justo7, Dorothy J Radford8, Robert G Weintraub9, Andrew Bullock10, David S Celermajer11, Yves d'Udekem12. 1. Department of Cardiac Surgery, Royal Children's Hospital, Melbourne, VIC, Australia Murdoch Childrens Research Institute, Melbourne, VIC, Australia Department of Paediatrics, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia ajayjiyengar@gmail.com. 2. Heart Centre for Children, The Children's Hospital at Westmead, Sydney, NSW, Australia University of Sydney, Sydney, Australia. 3. Murdoch Childrens Research Institute, Melbourne, VIC, Australia Department of Mathematics and Statistics, La Trobe University, Melbourne, VIC, Australia. 4. Department of Cardiology, Women's and Children's Hospital, Adelaide, SA, Australia. 5. Green Lane Paediatric and Congenital Cardiac Service, Starship Children's Hospital, Auckland, New Zealand. 6. Department of Cardiology, The Royal Melbourne Hospital, Melbourne, VIC, Australia. 7. Paediatric Cardiology, Queensland Paediatric Cardiac Service, Mater Children's Hospital, Brisbane, QLD, Australia. 8. Adult Congenital Heart Unit, The Prince Charles Hospital, Brisbane, QLD, Australia. 9. Murdoch Childrens Research Institute, Melbourne, VIC, Australia Department of Paediatrics, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia Department of Cardiology, Royal Children's Hospital, Melbourne, VIC, Australia. 10. Children's Cardiac Centre, Princess Margaret Hospital for Children, Perth, WA, Australia. 11. University of Sydney, Sydney, Australia Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 12. Department of Cardiac Surgery, Royal Children's Hospital, Melbourne, VIC, Australia Murdoch Childrens Research Institute, Melbourne, VIC, Australia Department of Paediatrics, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
Abstract
OBJECTIVES: To identify factors associated with hospital and long-term outcomes in a binational cohort of extracardiac conduit (ECC) Fontan recipients. METHODS: All patients who underwent an ECC Fontan procedure from 1997 to 2010 in Australia and New Zealand were identified, and perioperative, follow-up, echocardiographic and reintervention data collected. Risk factors for early and late mortality, failure and adverse outcomes were analysed. RESULTS: A total of 570 patients were identified, and late follow-up was available in 529 patients. The mean follow-up was 6.7 years (standard deviation: 3.5) and completeness of the follow-up was 98%. There were seven hospital mortalities (1%) and 21 patients (4%) experienced early failure (death, Fontan takedown/revision or mechanical circulatory support). Prolonged length of stay occurred in 10% (57 patients), and prolonged effusions in 9% (51 patients). Overall survival at 14 years was 96% (95% confidence interval [CI]: 93-98%), and late survival for patients discharged with intact Fontan was 98% (95% CI: 94-99%). The rates of late failure (late death, transplantation, takedown, New York Heart Association class III/IV or protein-losing enteropathy) and adverse events (late failure, reoperation, percutaneous intervention, pacemaker, thromboembolic event or supraventricular tachycardia) per 100 patient-years were 0.8 and 3.8, and their 14-year freedoms were 83% (95% CI: 70-91%) and 53% (95% CI: 41-64%), respectively. After adjustment for confounders, hypoplastic left heart syndrome (HLHS) was strongly associated with prolonged effusions (OR: 2.9, 95% CI: 1.4-5.9), late failure (hazard ratio [HR]: 2.8, 95% CI: 1.1-7.5) and adverse events (HR: 3.6, 95% CI: 1.3-7.5). CONCLUSIONS: The extracardiac Fontan procedure provides excellent survival into the second decade of life, but half of patients will suffer a late adverse event by 14 years. Patients with HLHS are at higher risk of late adverse events than other morphological groups, but their survival is still excellent.
OBJECTIVES: To identify factors associated with hospital and long-term outcomes in a binational cohort of extracardiac conduit (ECC) Fontan recipients. METHODS: All patients who underwent an ECC Fontan procedure from 1997 to 2010 in Australia and New Zealand were identified, and perioperative, follow-up, echocardiographic and reintervention data collected. Risk factors for early and late mortality, failure and adverse outcomes were analysed. RESULTS: A total of 570 patients were identified, and late follow-up was available in 529 patients. The mean follow-up was 6.7 years (standard deviation: 3.5) and completeness of the follow-up was 98%. There were seven hospital mortalities (1%) and 21 patients (4%) experienced early failure (death, Fontan takedown/revision or mechanical circulatory support). Prolonged length of stay occurred in 10% (57 patients), and prolonged effusions in 9% (51 patients). Overall survival at 14 years was 96% (95% confidence interval [CI]: 93-98%), and late survival for patients discharged with intact Fontan was 98% (95% CI: 94-99%). The rates of late failure (late death, transplantation, takedown, New York Heart Association class III/IV or protein-losing enteropathy) and adverse events (late failure, reoperation, percutaneous intervention, pacemaker, thromboembolic event or supraventricular tachycardia) per 100 patient-years were 0.8 and 3.8, and their 14-year freedoms were 83% (95% CI: 70-91%) and 53% (95% CI: 41-64%), respectively. After adjustment for confounders, hypoplastic left heart syndrome (HLHS) was strongly associated with prolonged effusions (OR: 2.9, 95% CI: 1.4-5.9), late failure (hazard ratio [HR]: 2.8, 95% CI: 1.1-7.5) and adverse events (HR: 3.6, 95% CI: 1.3-7.5). CONCLUSIONS: The extracardiac Fontan procedure provides excellent survival into the second decade of life, but half of patients will suffer a late adverse event by 14 years. Patients with HLHS are at higher risk of late adverse events than other morphological groups, but their survival is still excellent.
Authors: Geoffrey D Huntley; Abhishek J Deshmukh; Carole A Warnes; Suraj Kapa; Alexander C Egbe Journal: Pediatr Cardiol Date: 2018-06-14 Impact factor: 1.655
Authors: Ganesh K Gnanappa; David S Celermajer; Gary F Sholler; Tom Gentles; David Winlaw; Yves d'Udekem; Julian Ayer Journal: Pediatr Cardiol Date: 2016-10-27 Impact factor: 1.655
Authors: Lindsay R Freud; Doff B McElhinney; Audrey C Marshall; Gerald R Marx; Kevin G Friedman; Pedro J del Nido; Sitaram M Emani; Terra Lafranchi; Virginia Silva; Louise E Wilkins-Haug; Carol B Benson; James E Lock; Wayne Tworetzky Journal: Circulation Date: 2014-07-22 Impact factor: 29.690
Authors: Alexander C Egbe; Heidi M Connolly; William R Miranda; Naser M Ammash; Donald J Hagler; Gruschen R Veldtman; Barry A Borlaug Journal: Circ Heart Fail Date: 2017-12 Impact factor: 8.790
Authors: Alexander C Egbe; Yogesh N V Reddy; Arooj R Khan; Mohamad Al-Otaibi; Emmanuel Akintoye; Masaru Obokata; Barry A Borlaug Journal: Int J Cardiol Date: 2018-11-15 Impact factor: 4.164
Authors: Nigel E Drury; Victoria M Stoll; Chris J Bond; Akshay J Patel; Suzie Hutchinson; Paul F Clift Journal: Cardiol Young Date: 2018-12-21 Impact factor: 1.093
Authors: Karin du Plessis; Rebecca Peters; Ingrid King; Kirsty Robertson; Jonathan Mackley; Rachel Maree; Tracy Stanley; Louise Pickford; Brian Rose; Matthew Orchard; Helen Stewart; Yves d'Udekem Journal: Int J Cardiol Heart Vasc Date: 2018-03-09